.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,633,352

« Back to Dashboard

Summary for Patent: 5,633,352

Title: Biosynthetic human growth hormone
Abstract:A desired protein having the formula: wherein a) A is Lys or Arg, and B and C are arbitrary amino acids, or b) A is an arbitrary amino acid different from Pro, Lys and Arg, and B and/or C is Pro, is produced from a biosynthetically formed amino acid extended protein having the formula: wherein A, B, C and P are as defined above, and X is an amino acid sequence with an even number of amino acids, of which the first one, seen from the N-terminal end, is different from Lys and Arg, all other uneven amino acids are different from Pro, Lys and Arg, and all even amino acids are different from Pro, by reaction with the enzyme dipeptidyl aminopeptidase (DAP I). The desired protein is obtained in a pure state. Thus, e.g. hGH without content of Met-hGH may be produced by the process.
Inventor(s): Dalb.o slashed.ge; Henrik (Virum, DK), Pedersen; John (Kokkedal, DK), Christensen; Thorkild (Aller.o slashed.d, DK), Ringsted; J.o slashed.rli W. (Br.o slashed.ndby, DK), Jessen; Torben E. (Holbaek, DK)
Assignee: Novo Nordisk A/S (DK)
Application Number:08/402,286
Patent Claim Types:
see list of patent claims
Compound;
Patent PDF download available with subscription

No matches for this query

Foreign Priority and PCT Information for Patent: 5,633,352

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark5493/82Dec 10, 1982
Denmark556/85Feb 07, 1985

International Patent Family for Patent: 5,633,352

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria30246<disabled in preview>
Austria52807<disabled in preview>
Australia2331784<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc